RxDoctor Payments Data

Natalie Bee, PA

Physician Assistant · Salt Lake City, UTNPI 1841701760

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $56,547 of the $62,519 with a category attached, or 90.4%. 23 manufacturers reported payments, led by Organon at 47.3% of the total. Reporting peaked in 2021 at $34,105 and has fallen 78.1% since, to $7,485 in 2025. Among physician assistant clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,519in general payments, 2019–2025

Across 290 payments — averaging $215.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$30K
  • Biohaven Pharmaceuticals, Inc.$27K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • AbbVie$1K
  • Novo Nordisk$178
  • Takeda Pharmaceuticals U.S.A., Inc.$159
  • plus $693 from 17 others

What the payments were for

  • Consulting fees$8001%
  • Speaking & faculty fees$56,54790%
  • Travel & lodging$1,3042%
  • Food & beverage$3,8566%
  • Education$120%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,519 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$22,913
Medicare patients
140
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$30,548
TrulicityDulaglutide13$16,808
XareltoRivaroxaban14$14,068
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,712
Bupropion XlBupropion Hcl35$1,333
Gabapentin56$1,325
Duloxetine Hcl35$1,237
Omeprazole70$1,037
ValacyclovirValacyclovir Hcl17$892
Albuterol Sulfate HfaAlbuterol Sulfate35$844
Rosuvastatin Calcium25$808
Atorvastatin Calcium111$734
Trazodone Hcl45$700
Levothyroxine Sodium81$613
Lisinopril79$397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$178$30,54826 claims
Lilly USA, LLCTrulicity$61$16,80813 claims
Johnson & JohnsonXarelto$14$14,06814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →